Favorable Immune Profile Linked to VT1021 Treatment Response in rGBM
Patients treated with VT1021 for recurrent glioblastoma were found to have immune markers associated with response to treatment in a phase 1/2 study.
Related Articles
Emerging Therapies for Chronic Graft-Versus-Host Disease
This segment of the virtual tumor board presentation focuses on the clinical development and use of emerging therapies, specifically Belumosudil, for the management of chronic…
CAR T-Cell Therapy Broadens Second-Line Treatment in LBCL
Matthew Lunning, DO, FACP, discusses the use of CAR T-cell therapy lisocabtagene maraleucel in the second-line setting for patients with B-cell lymphoma.
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Monitoring and Managing Anemia in Patients on Ruxolitinib
Dr. Bose shares his perspective on how he monitors and manages anemia for patients on ruxolitinib, including when he would consider dose reduction or transfusion.
Phase 2 Study of Glecirasib Meets Primary End Point in KRAS G12C-Mutant NSCLC
A pivotal phase 2 study evaluating glecirasib for the treatment of KRAS G12C-mutated advanced non-small cell lung cancer met its primary end point with an…
FRESCO-2 Study Design Overview
Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients…
New FDA Guidance Looks to Improve Clinical Trial Enrollment and Diversity
Recently published guidelines from the FDA aim to expand eligibility criteria in clinical trials with recommendations for laboratory values, washout periods, and patient performance status.
FDA Clears IND of PRAME TCR-IL-15 NK Program for R/R Myeloid Malignancies
The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.
Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC
During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell…
Secondary Malignancies After CAR T: How Big is the Risk?
Binod Dhakal, MD, MS, discusses the potential risk of secondary cancers like lymphoma and leukemia sometimes seen with chimeric antigen receptor T-cell therapies.